HIV Treatment Bulletin - Vol. 6, No. 9, September 2005
Polly Clayden, HIV i-Base

As of March 2005, Médicins Sans Frontières (MSF) had 36,000 patients on HAART worldwide, 2,300 of these are children <13 years old.

In a late breaker presentation Pierre Humblet from MSF presented data showing favourable outcomes from a cohort of 1,840 children <13 years old receiving HAART in 11 MSF programmes across Africa.

Of those receiving treatment 883 (48.4%) were girls and there were few very young infants - 96% were older than 18 months (median age 5.9 years IQR 3.6-8.3). The majority of the children (85%) had a CD4 percentage of <15% on initiation of therapy.

Ninety seven percent of the children received WHO recommended first line combinations, and 65% received cut up fixed dose combination Triomune (3TC/d4T/nevirapine) tablets.

Median follow up for the children was 6.9 months, with 54% having over 6 months and 29% over 12 months. The investigators reported a median CD4 percentage increase of + 9%, +11% and +13% at 6, 12 and 24 months respectively, and a median weight gain of + 2kg, + 3kg and +5kg at the same months of follow up.

The investigators reported that as of March 2005 1543 (84%) of children were alive and on treatment, 111 (6%) had died, 79 94%) were lost to follow up, 28 (1.5%) stopped treatment, 3 (0.2%) transferred and 76 (4%) had unknown. One hundred and three (5.6%) children reported side effects causing 79 (4.3%) to switch drugs. Only 4 children have so far required second line therapy. Survival at 6,12 and 24 months was 94%, 92% and 91% respectively.

The authors wrote: “This data shows very satisfactory outcomes (comparable to those in developed countries) among children offered HAART under routine programme conditions in resource-limited settings. They continue: “Our findings strongly favour the rapid integration of HAART for children within the scaling up process in these settings.”

Dr Humlet acknowledged that the study has limitations. So far, there are no virological outcomes for the children, the systems of reporting are not standardised, and side effects are probably underreported. He added that only 6% of the patients in the MSF cohort currently receiving HAART are children. Furthermore, that obstacles are lack of paediatric fixed dose combinations and confidence of healthcare workers to treat children.

Ref: AIDS Working Group, Epicentre, Médicins Sans Frontières. Very satisfactory outcomes can be achieved in children treated with highly active antiretroviral treatment under programme conditions in resource-limited settings: the experience of Médicins Sans Frontières. IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: (Abstract No. WeOaLB0201).

050910
IB050609-07

©2005. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.